The Effect of Autonomic Function on Coronary Vasomotion

Sponsor
Korea University (Other)
Overall Status
Completed
CT.gov ID
NCT01877993
Collaborator
Korea Institute of Science and Technology (Other)
2,169
3
3
723
239.2

Study Details

Study Description

Brief Summary

Autonomic nerve function is involved in both blood pressure (BP) regulation and the pathogenesis of coronary artery spasm (CAS), but few studies have been published about the relationship between CAS and BP, with the exception of studies that explore hypertension as a risk factor for CAS. The purpose of this study was to investigate the incidence of CAS and atrioventricular (AV) block in association with BP level. The investigators will register consecutive patients who underwent coronary angiography with an acetylcholine (Ach)-induced provocation test from November 2004 to May 2012. The investigators exclude from the patients who were taking antihypertensive drugs or who had a documented history of cardiovascular disease in order to avoid the confounding effects of cardiovascular medications on coronary vasomotion. CAS is defined as >70% luminal narrowing on Ach provocation and /or concurrent chest pain. The study population will be divided into quartiles of rising systolic BP and diastolic BP. The incidence of Ach-induced CAS according to each systolic BP/diastolic BP quartile will be evaluated.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    A total of consecutive patients in the CAS registry of the Cardiovascular Center at Korea University Guro Hospital and who had resting chest pain without significant coronary lesions (luminal narrowing <50%) underwent a provocation test with Ach infusion during coronary angiography from November 2004 to May 2012 will be registerd. Among them, patients with documented cardiovascular disease and/or any other serious medical condition, such as an increased serum creatinine level (>2mg/dl), will be excluded. Patients will be excluded due to incomplete data. The study population will be divided into quartiles based on rising systolic BP, diastolic BP, and pulse pressure. Each group will be defined as following criteria: 1) group 1: systolic BP <117mmHg, diastolic BP <69mmHg, and pulse pressure <42mmHg; 2) group 2: systolic BP 117-130 mmHg, diastolic BP 69-77 mmHg, and pulse pressure 42-51mmHg; 3) group 3: systolic BP 131-141 mmHg, diastolic BP 78-86 mmHg, and pulse pressure 52-61mmHg; and 4) group 4: systolic BP >141 mmHg, diastolic BP >86 mmHg, and pulse pressure >61mmHg. CAS+Chest Pain means>70% luminal narrowing on Ach provocation test. and/or concurrent typical chest pain. BP was measured with a noninvasive BP monitoring device with the patient lying on the angiographic table after a five-minute rest (Patient monitoring system, NP 30:Philips, Amsterdam, The Netherlands). The first reading was discarded, and the mean of the next two consecutive readings was used. Next, coronary angiography was performed. Hypertension is defined as systolic BP ≥140mmHg and/or diastolic BP ≥90mmHg on at least two consecutive readings in the outpatient clinic. Patients taking antihypertensive medications are also categorized as hypertensives. Other Risk factors for CAS examined in this study include hyperlipidemia (total cholesterol level ≥200mg /dl or current medication with lipid-lowering drugs), diabetes (fasting blood glucose≥126mg /dl, and/or glycated Hemoglobin A1c level more than 6.5% or current use of medications), current smoker (active smoking within the past 12 months), and current alcohol user (at least 1 alcohol drinking a week).

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    2169 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Association of Acetylcholine-induced Coronary Artery Spasm With the Blood Pressure Level
    Study Start Date :
    May 1, 2013
    Actual Primary Completion Date :
    Aug 1, 2013
    Actual Study Completion Date :
    Aug 1, 2013

    Outcome Measures

    Primary Outcome Measures

    1. development of significant CAS [during the Ach provocation test]

      During the Ach provocation test, significant CAS was recorded when present, and we recorded whether it was associated with any of the four following criteria: 1) chest pain only during Ach provocation test 2) >70% luminal narrowing on coronary angiography and concurrent typical chest pain;3) >70% luminal narrowing on coronary angiography and/or concurrent chest pain and EKG changes(ST-segment elevation or depression ≥1mm); 4) >90% luminal narrowing induced by A3 dose on coronary angiography and/or concurrent chest pain.

    Secondary Outcome Measures

    1. Transient high-grade AV block [occurred in response to Ach injection]

      Transient high-grade AV block that occurred in response to Ach injection is defined as such if it consisted of multiple sequential P waves that should conduct, but did not.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients had resting chest pain without significant coronary lesions (luminal narrowing <50%) underwent a provocation test with Ach infusion during coronary angiography.
    Exclusion Criteria:
    • patients with documented cardiovascular disease and/or any other serious medical condition, such as an increased serum creatinine level (>2mg/dl), patients with incomplete data, and patients who had been diagnosed with hypertension or were currently using antihypertensive medications.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Internal Medicine, Division of Cardiology, Sanbon Hospital, Wonkwang University Gunpo Gyeonggi-do Korea, Republic of
    2 Hong Seog Seo Seoul Korea, Republic of 152-703
    3 Korea Institute of Science and Technology Seoul Korea, Republic of

    Sponsors and Collaborators

    • Korea University
    • Korea Institute of Science and Technology

    Investigators

    • Principal Investigator: Hong Seog Seo, MD, Ph., Korea University Guro Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hong Seog Seo, Professor of Medicine, Korea University
    ClinicalTrials.gov Identifier:
    NCT01877993
    Other Study ID Numbers:
    • BP-CAS
    First Posted:
    Jun 14, 2013
    Last Update Posted:
    Aug 27, 2013
    Last Verified:
    Aug 1, 2013
    Keywords provided by Hong Seog Seo, Professor of Medicine, Korea University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 27, 2013